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Glucosamine Hydrochloride but Not 
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Degradation and Inflammation Induced by 
Interleukin-1α in Bovine Cartilage Explants 
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John L. Harwood1, Bruce Caterson1, and Clare E Hughes1 
Abstract 
Objective. Glucosamine hydrochloride (GH) and chondroitin sulfate (CS) are commonly used for the treatment of 
osteoarthritis (OA). The aim of this study was to assess their effects, alone and in combination, on preventing 
aggrecan degradation and inflammation in an in vitro model of OA. Design. To test the effects of GH and/or CS as 
a preventative treatment, cartilage explants were pretreated with the compound(s) using concentrations that showed 
no detrimental effect on chondrocyte viability. Interleukin-1α (IL-1α) was added to induce cartilage degradation, 
supernatant and explants were analyzed for proteoglycan degradation products, aggrecanase mRNA expression 
and activity, and for the release of inflammatory markers. Results. Following treatment with IL-1α, 2 mg/mL dose of 
GH pretreatment was associated with a reduction of glycosaminoglycan release, reduced generation of the 
pathological interglobular domain aggrecan catabolites, decreased mRNA levels of ADAMTS-4 and -5 and reduced 
activity of ADAMTS-4. In contrast, CS alone did not have a significant effect on IL-1α-induced cartilage degradation 
and the addition of 0.4 mg/mL CS to 2 mg/mL GH did not further inhibit IL-1α-induced activity. Pretreatment with 2 
mg/mL GH also reduced the release of inflammatory markers, prostaglandin E2 and nitric oxide induced by IL-1α 
while CS did not have a significant effect. Conclusions. The results suggest that GH prevents cartilage degradation 
mediated by aggrecanases ADAMTS-4 and -5, and may also reduce inflammation. This could be part of the 
mechanisms by which GH is effective in maintaining joint integrity and function, and preventing or delaying early 
symptoms of OA. 
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Introduction 
Osteoarthritis (OA) is a degenerative disease of the joints 
characterized by a loss of articular cartilage and remodeling 
of subchondral bone. More than 8.75 million people are 
affected in the United Kingdom and about 27 million people 
in the United States.1,2 Conventional treatments, which 
mainly include analgesics and nonsteroidal anti-
inflammatory drugs, can cause serious side-effects. With no 
cure for OA, agents that not only reduce the pain but also 
prevent or at least slow down the progression of the disease 
are desirable and in this study we are interested in testing 
the 2 commonly used nutraceuticals, glucosamine and 
chondroitin, to prevent or delay the pathological changes in 
cartilage that manifest during the early stages of the disease. 
Aggrecan consists of a core protein with 100 to 150 
glycosaminoglycan (GAG) chains attached to it. Along with 
type-II collagen, aggrecan forms a major structural 
component of articular cartilage. The loss of aggrecan from 
articular cartilage is an early event in the development of 
OA and continued loss of aggrecan leads to the 
susceptibility of the collagen network to proteolysis and 
irreversible tissue damage.3-5 Metalloproteinases, namely 
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ADAMTS-4 and ADAMTS-5 (A Disintegrin And 
Metalloproteinase with Thrombospondin motifs) also 
referred to as aggrecanase 1 and 2, are the key enzymes 
involved in the degradation of aggrecan in normal and 
osteoarthritic cartilage.6-8 Prevention of early loss of 
aggrecan during the disease process is likely to contribute 
to a slowing in the progression of the disease and therefore 
to improved joint health. 
Glucosamine, an amino monosaccharide, and 
chondroitin, a polysaccharide macromolecule, are both 
present naturally in cartilage. In clinical trials, consumption 
of either glucosamine or chondroitin sulfate (CS) has been 
associated with a reduction in joint pain, improvement of 
joint function and reduction of joint space narrowing in 
patients with OA.9-22 However, there is conflicting evidence 
as to the effectiveness of such treatments.23-30 In vitro 
studies using glucosamine alone have found positive effects 
such as decreased interleukin-1 (IL-1) induced expression 
of matrix metalloproteinases, MMP-3 and MMP-13, 
cyclooxygenase-2 (COX-2), and nitric oxide synthase, 
reduced aggrecan degradation, and increased synthesis of 
aggrecan core protein31-36 while others have found a 
decrease in prostaglandin E2 (PGE2) production induced by 
IL-1.36,37 Studies using CS alone have shown that CS has 
anti-inflammatory and chondroprotective actions.38-40 
The aim of this research was to determine whether 
glucosamine hydrochloride (GH) and CS, individually and 
in combination, could inhibit the cytokine-induced 
catabolism of aggrecan in vitro and to elucidate 
mechanisms specific to each compound or to the 
combination. While clinical trials and most in vitro studies 
have focused on the effects of glucosamine and CS after the 
appearance of the symptoms or after the induction of OA-
like pathology in vitro, the present study focuses on the 
preventive effects. 
Methods 
Viability of Chondrocyte Monolayer Cell 
Cultures 
Chondrocytes from the metacarpophalangeal joint of 18 
month-old oxen showing no visible signs of cartilage 
degeneration were isolated as previously described.41 
Chondrocyte monolayer cultures were established in sterile 
12-well plates (Corning Incorporated) at 1 × 106 cells per well 
in 2 mL basal medium: Dulbecco’s modified Eagle medium 
(DMEM) containing 50 µg/mL gentamicin and 1% Insulin-
Transferrin-Selenium-X supplement (ITS, Invitrogen). Cells 
were incubated overnight and medium was then replaced 
with 2 mL basal medium with GH or CS in a range of 0 to 4 
mg/mL, or with a combination of 2 mg/mL GH and 0.4 
mg/mL CS. This dose combination of GH and CS was based 
on the formulation of an emulsified product available on the 
market (VeryWise Nutrition) where the proportion of the 2 
compounds was kept consistent (GH:CS, 5:1, w/w). GH and 
CS (from bovine cartilage) were supplied by Obsidian 
Research Ltd. Cultures were maintained and tested for cell 
viability using the thiazolyl blue tetrazolium bromide (MTT) 
assay.43 Chondrocyte monolayer cultures were generated 
from articular cartilage collected and pooled from 3 different 
joints. Each experimental condition was replicated 3 times (n 
= 3). 
Articular Cartilage Explants and Treatments 
Articular cartilage was dissected from the 
metacarpophalangeal joints of 18-month-old oxen showing 
no visible signs of cartilage degeneration, Cartilage 
explants (15-60 mg wet weight) were maintained in DMEM 
containing 10% (v/v) fetal calf serum and 50 µg/mL 
gentamicin for 3 days.44 Cartilage explants were then 
maintained individually in 1 mL of basal medium or 1 mL 
of basal medium with test concentrations of either GH or 
CS, or a combination of both. Following 24-hour 
incubation, human IL-1α (PeproTech Inc.) was added to 
appropriate wells at 10 ng/mL final concentration such that 
the following experimental conditions were obtained and 
maintained for a further 24 or 72 hours: 
CS and GH individually: (a) basal medium (control); (b) 
basal medium + IL-1; (c) basal medium + 0.2 mg/mL CS 
or GH; (d) basal medium + 0.2 mg/mL CS or GH + IL-
1; (e) basal medium + 2 mg/mL CS or GH; (f) basal 
medium + 2 mg/mL CS or GH + IL-1 
GH and CS combination: (a) basal medium (control); (b) 
basal medium + IL-1; (c) basal medium + 2 mg/mL GH; 
(d) basal medium + 2 mg/mL GH + IL-1; (e) basal 
medium + 0.4 mg/mL CS; (f) basal medium + 0.4 
mg/mL CS + IL-1; (g) basal medium + 2 mg/mL GH + 
0.4 mg/mL CS; (h) basal medium + 2 mg/mL GH + 0.4 
mg/mL CS + IL-1. 
A series of explants were treated for each condition, 
using cartilage taken from 3 different joints (n = 3). 
Explants and culture supernatant were harvested and stored 
at −80°C prior to analysis. 
Measurement of Sulfated-
Glycosaminoglycans 
Sulfated-glycosaminoglycan (s-GAG) release from 
cartilage explants into the culture supernatant was measured 
at 72 hours after the addition of IL-1α, using the 1,9-
dimethylmethylene blue (DMMB) assay.45 Where 
appropriate, s-GAG released into the culture supernatant 
was calculated by subtracting the s-GAG measured in basal 
media containing CS at the appropriate concentration. This 
calculation allowed for the subtraction of s-GAG in the CS 
added to the basal medium prior to incubation with the 
cartilage explant. The effect of treatments on the release of 
s-GAG was expressed as micrograms (µg) GAG per 
milligram (mg) wet weight of cartilage explant. 
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Western Blot Analysis of Interglobular 
Domain (IGD) Aggrecan Catabolite ARGSVIL 
Western blotting with monoclonal antibody BC-3 
recognizing the new N-terminal neoepitope ARGSVIL on 
aggrecanase-generated interglobular domain (IGD) 
fragments was used to assess the effect of GH and CS on 
the generation of the pathological aggrecan catabolic 
products after IL-1α stimulation.46 BC-3 antibody42 was 
provided in-house (Cardiff University). Samples of culture 
supernatants (equivalent of 2 mg wet weight of tissue) 
collected 72 hours after the addition of IL-1α were 
deglycosylated, dialyzed, and lyophilized as previously 
described.41,47 Samples were reconstituted and separated on 
4% to 12% Novex Tris-glycine sodium dodecyl sulfate–
polyacrylamide gel electrophoresis gels (Invitrogen). After 
transfer to nitrocellulose membranes the BC-3 antibody was 
used to recognize the N-terminal ARGSVIL generated by 
aggrecanase cleavage of the bovine aggrecan core protein at 
the Glu373-Ala374 bond.41,42 Membranes were developed 
using alkaline phosphatase (AP) substrate. The density of 
the bands was measured and expressed as the area under the 
signal intensity curve (AUC, in arbitrary units) using the 
ImageJ software (NIH Image). 
Measurement of mRNA Expression of 
ADAMTS-4 and ADAMTS-5 
Total RNA was isolated from the cartilage explants 
collected 24 hours after the addition of IL-1α. Explants were 
snap-frozen in liquid nitrogen and reduced to a fine powder 
using a Mikro-Dismembrator (Braun Biotech 
International). RNA was extracted using Tri reagent and 
was then isolated using Qiagen RNeasy mini-columns and 
reagents according to the manufacturer’s protocol. RNA 
was eluted in sterile RNAase free water and samples were 
stored at −80°C. Complementary DNA (cDNA) was 
synthesized from 500 ng RNA by reverse transcription 
using Moloney Murine Leukemia Virus (MuLV) reverse 
transcriptase (New England BioLabs). Quantitative real-
time polymerase chain reaction (PCR) amplification was 
performed using an Mx qPCR System (Agilent 
Technologies). Sequence of specific oligonucleotide 
primers corresponding to the genes of interest, ADAMTS-
4 and ADAMTS-5, are listed in Table 1. Serial dilutions 
from 1 × 107 copies/µL to 1 × 101 copies/µL of a plasmid 
containing the corresponding genes were used as standards 
to quantify the expression of ADAMTS-4 and ADAMTS-
5. Brilliant SYBR Green qPCR Master Mix (Stratagene) 
was used for the qPCR reactions with 1 µL cDNA or 
plasmid. The amplification cycle used was as follows: 
initial denaturation for 30 seconds at 95°C (1 cycle), 30 
seconds at 95°C followed by 45 seconds at annealing 
temperature and 1 minute, elongation at 72°C (40 cycles), 
and a final extension for 5 minutes at 72°C (1 cycle). 
Melting curves were evaluated for each gene and the fold 
change in gene expression relative to the control (no 
treatment, no IL-1α) was expressed using the copy number 
calculated from the plasmid standards. 
Measurement of ADAMTS-4 Activity 
ADAMTS-4 activity was measured in culture supernatant 
collected 72 hours after IL-1α stimulation, using the 
SensoLyte 520 Aggrecanase-1 fluorimetric assay kit from 
AnaSpec. Results were expressed as relative fluorescence 
normalized to tissue wet weight (in milligrams). 
Table 1. Primers Used for Quantitative Real-Time Polymerase 
Chain Reaction (PCR). 
Target Gene 
PCR Primer  
Sequence (5′-3′) 
Annealing 
Temperature 
(°C) 
Product 
Size  
(bp) 
ADAMTS-4 AAGTTCGACAAGTGC
ATGGTG 
TATTCACCGTTGAGG
GCATAG 
57 215 
ADAMTS-5 CAAATGTGGCGTCTG
TGGAGG 
TCCCGTTGATGTCGA
TGATGG 
57 254 
Measurement of Prostaglandin E2 
PGE2 was measured in tissue culture supernatant collected 
at 72 hours after the addition of IL-α, using a competitive 
ELISA kit (R&D Systems) with standards of PGE2 (0-2500 
pg/mL). Results were expressed as picograms of PGE2 per 
milligram tissue wet weight. 
Nitric Oxide Assay 
Nitric oxide (NO) was measured in tissue culture 
supernatant collected at 72 hours after the addition of IL-α, 
using the Griess reaction and standards of sodium nitrite (0-
100 µM) from the Griess Reagent System (Promega) 
following the manufacturer’s protocol. Absorbance was 
measured at 540 nm and results were expressed as 
nanomoles NO per milligram tissue wet weight. 
Statistical Analyses 
Each condition was carried out using cartilage explants (n = 3) 
from 3 individual joints. Analyses were carried out on the 3 
replicate samples (cartilage explant or media supernatant) from 
each of the individual joints. Results were expressed as mean 
(± standard deviation [SD] or standard error of the mean 
[SEM]) of the 3 samples from the 3 joints. SD was applied to 
the results from cell viability experiments and SEM was 
applied to the results of all experiments using explants. One-
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sample Student t test was used to compare means. Differences 
were considered significant at P < 0.05. 
Results 
Effects of Chondroitin Sulfate and 
Glucosamine Hydrochloride on Chondrocyte 
Viability 
At concentrations of 0.02 to 4 mg/mL, CS had little effect 
or increased the metabolic activity of the chondrocytes 
above that seen in controls (Fig. 1A). GH in a range of  
 
 
 
Figure 1. Cellular metabolic activity of chondrocytes with chondroitin sulfate (A) and glucosamine hydrochloride (B), assessed 
individually and in combination (C) using MTT assay. Values represent the mean relative absorbance to the control without 
treatment ± SD, n = 3. One-sample Student t test was used. *Indicates P < 0.05 for a comparison with the control without 
glucosamine hydrochloride (GH) and/or chondroitin sulfate (CS). 
 
0.02 to 2 mg/mL resulted in no major change in cellular 
metabolic activity except at 4 mg/mL there was a large 
decrease in metabolic activity, with 70% and 13% average 
relative absorbance after 4 and 7 days in culture, 
respectively (Fig. 1B), suggesting that high concentrations 
of GH have toxic effects on chondrocyte viability and/or 
metabolism. The combination 2 mg/mL GH and 0.4 mg/mL 
CS showed no detrimental effect on chondrocyte viability 
(Fig. 1C). Unlike the first experiment (Fig. 1B), GH at 2 
mg/mL showed an increase in chondrocyte cellular 
metabolic activity after 7 days in culture (Fig. 1C). As 
expected, CS at 0.4 mg/mL showed no substantial change 
in metabolic activity (Fig. 1C). Interestingly, the 
combination of GH and CS resulted in an increase in 
cellular metabolic activity following 7 days in culture, with 
139% relative absorbance (Fig. 1C). Concentrations of GH 
and CS that did not appear detrimental to chondrocyte 
viability over a period of 7 days were used to test their 
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potential effects in preventing cartilage degradation induced 
by IL-1α. 
Glucosamine Hydrochloride Alone or with 
Chondroitin Sulfate Suppresses Proteoglycan 
Degradation Induced by IL-1α 
Stimulation of cartilage explants in culture with 10 
ng/mL IL-1α significantly induced the release of s-GAG 
from the extracellular matrix (P < 0.05, Fig. 2). CS 0.2 
mg/mL decreased s-GAG release induced by IL-1α 
significantly (P < 0.001, Fig. 2A) while CS at 2 mg/mL 
increased s-GAG release further when compared with  
 
 
 
 
 
Figure 2. Sulfated glycosaminoglycan (s-GAG) release measured using DMMB assay in tissue culture supernatant at 72 hours 
poststimulation with interleukin-1α (IL-1α), in the presence of chondroitin sulfate (A) and glucosamine hydrochloride (B) 
individually, and with a combination (C). Values represent the mean GAG release in µg per mg of tissue ± SEM, n = 3. One-
sample Student t test was used. §Indicates P < 0.05 for a comparison with the control without IL-1α stimulation. #Indicates P < 
0.05 for a comparison with the control with IL-1α stimulation. 
 
control with IL-1α (P < 0.05, Fig. 2A). GH 0.2 mg/mL 
had no significant effect on s-GAG release induced by 
IL-1α (Fig. 2B), while GH at 2 mg/mL prevented s-GAG 
release induced by IL-1α significantly (P < 0.05, Fig. 
2B). Consistently, GH at 2 mg/mL as well as GH at 2 
mg/mL + CS 0.4 mg/mL significantly inhibited the 
release of endogenous aggrecan loss from the matrix of 
articular cartilage explants stimulated with 10 ng/mL IL-
1α compared with control with IL-1α (P = 0.002 for both, 
Fig. 2C). However, 0.4 mg/mL CS alone did not inhibit 
this loss of aggrecan (Fig. 2C). 
IL-1α-treated cartilage explants released BC-3 positive 
interglobular domain (IGD) fragments into the culture 
media, typically generating molecular mass fragments of 
around 50, 60, and 150 kDa (Fig. 3A2-3C2; IL-1). 
Reduction in staining for BC-3 positive catabolites was seen 
in cultures pretreated with GH at 2 mg/mL (Fig. 3B2 and 
3C2) and GH at 2 mg/mL + CS 0.4 mg/mL (Fig. 3C2), 
without further decrease with the addition of CS at 0.4 
mg/mL and there was no reduction in staining for BC-3 
positive bands in cultures pretreated with CS alone (Fig. 
3A2). Densitometric analysis of samples from 3 separate 
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experiments showed a significant reduction of aggrecan loss 
induced by IL-1α in GH 2 mg/mL only or GH 2 mg/mL + 
CS 0.4 mg/mL pretreated cultures (P < 0.05, Fig. 3B1 and 
3C1). 
Glucosamine Hydrochloride Suppresses IL-1α-
Induced Gene Expression of ADAMTS-4 and 
ADAMTS-5 
In control explants without treatment, the mRNA 
expression of ADAMTS-4 was low and stimulation with 
IL-1α increased the expression of ADAMTS-4 mRNA, but 
the increase was not statistically significant (P = 0.076, Fig. 
4A). An increase in ADAMTS-4 mRNA expression was 
also seen in cultures treated with GH 2 mg/mL alone but 
was not statistically significant (P = 0.095, Fig. 4A), and 
this effect was negated with the addition of CS 0.4  
 
 
 
 
 
Figure 3. Western bolt analysis of tissue culture supernatant using BC-3 antibody to assess the effect of chondroitin sulfate (A) 
and glucosamine hydrochloride (B) individually and in combination (C) on the level of aggrecanases products at 72 hours 
poststimulation with interleukin-1α (IL-1α). (1) Densitometry was used to measure the overall density of the bands. Values represent 
the mean area under the curve (AUC) in arbitrary units ± SEM, n = 9. #Indicates P < 0.05 for a 1-sample Student t test comparison 
with the control with IL-1α stimulation. (2) Representative BC-3 Western blots. M: Molecular mass marker. 
 
mg/mL (Fig. 4A). In cultures stimulated with IL-1α, in the 
presence of GH 2 mg/mL or GH 2 mg/mL + CS 0.4 mg/mL, 
a reduction of ADAMTS-4 mRNA expression was seen 
compared with the control with IL-1α but was not 
statistically significant (P = 0.077 and P = 0.138, 
respectively, Fig. 4A). Pretreatment with CS 0.4 mg/mL 
only had no significant effect on the expression of 
ADAMTS-4 mRNA (Fig. 4A). 
ADAMTS-5 mRNA was constitutively expressed in 
control cartilage explants and stimulation with IL-1α 
significantly increased expression of ADAMTS-5 (P = 
0.007, Fig. 4B). As observed for ADAMTS-4, the mRNA 
expression of ADAMTS-5 was also significantly increased 
in cultures containing GH 2 mg/mL alone (P = 0.015, Fig. 
4B), and this effect was lessened with the addition of CS 0.4 
mg/mL (Fig. 4B). Pretreatment with GH 2 mg/mL or GH 2 
mg/mL + CS 0.4 mg/mL suppressed the expression of 
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ADAMTS-5 mRNA induced by IL-1α. The effect was 
significant with GH 2 mg/mL alone but not with GH 2 
mg/mL + CS 0.4 mg/mL compared with control with IL-1α 
(P = 0.014 and P = 0.157, respectively, Fig. 4B). As 
observed for ADAMTS-4, pretreatment with CS 0.4 mg/mL 
had no significant effect on the expression levels of 
ADAMTS-5 mRNA (Fig. 4B). 
Glucosamine Hydrochloride Only or with 
Chondroitin Sulfate Suppresses IL-1α-Induced 
Activity of ADAMTS-4 
The mean relative activity of ADAMTS-4 in controls was 
significantly increased with IL-1α stimulation (P = 0.054, 
Fig. 5). With GH 2 mg/mL or GH 2 mg/mL + CS 0.4 
mg/mL and IL-1α stimulation, the mean ADAMTS-4 
activity was decreased compared with that of the control 
with IL-1α stimulation, but this was not statistically 
significant (Fig. 5). When compared with the samples 
without IL-1α stimulation, GH 2 mg/mL or GH 2 mg/mL + 
CS 0.4 mg/mL prevented a significant increase of the 
relative activity of ADAMTS-4 induced by IL-1α (P = 
0.236 and P = 0.518, respectively, Fig. 5). 
 
 
 
 
Figure 4. ADAMTS-4 mRNA expression (A) and ADAMTS-5 mRNA expression (B) at 24 hours poststimulation with interleukin-1α 
(IL-1α), with chondroitin sulfate (CS) and glucosamine hydrochloride (GH) pretreatment. Values represent the mean fold change 
in expression relative to the control without IL-1α ± SEM, n = 3. One-sample Student t test. §Indicates P < 0.05 for a comparison 
with the control without IL-1α stimulation. #Indicates P < 0.05 for a comparison with the control with IL-1α stimulation. 
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Figure 5. Effect of glucosamine hydrochloride (GH) and chondroitin sulfate (CS) on ADAMTS-4 activity at 72 hours poststimulation 
with interleukin-1α (IL-1α). Values represent the mean relative fluorescence per mg tissue ± SEM, n = 3. One-sample Student t 
test was used. Check symbol indicates P < 0.05 for comparison between no-IL-1α and IL-1α control samples. 
 
 
 
Figure 6. Effect of glucosamine hydrochloride (GH) and chondroitin sulfate (CS) on prostaglandin E2 (PGE2) production (A) and 
on nitric oxide (NO) production (B) at 72 hours poststimulation with interleukin-1α (IL-1α). (A) Values represent the mean PGE2 
level expressed in pg per mg tissue ± SEM, n = 3. (B) Values represent the mean NO level expressed in nanomoles per mg tissue 
± SEM, n = 3. One-sample Student t test was used. Check symbol indicates P < 0.05 for comparison between no-IL-1α and IL-1α 
samples with the same treatment. #Indicates P < 0.05 for a comparison with the control with IL-1α stimulation. 
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Glucosamine Hydrochloride Only or with 
Chondroitin Sulfate Decreases IL-1α-Induced 
Release of Prostaglandin E2 and Nitric Oxide 
In control cultures or with CS 0.4 mg/mL, the level of PGE2 
was significantly increased by IL-1α (P = 0.002 and P = 
0.034, respectively, Fig. 6A). In the presence of GH 2 
mg/mL or the combination GH 2 mg/mL + CS 0.4 mg/mL, 
PGE2 average concentration was reduced when compared 
with the IL-1α-treated control, significantly with GH alone 
(P = 0.005, Fig. 6A). 
A significant increase in NO concentration was seen in 
all cultures stimulated with IL-1α (P < 0.01, Fig. 6B). In 
GH 2 mg/mL and GH 2 mg/mL + CS 0.4 mg/mL pretreated 
cultures, the increase in NO generated by stimulation with 
IL-1α was significantly suppressed when compared with 
control with IL-1α (P = 0.009 and P = 0.010, respectively, 
Fig. 6B). 
Discussion 
Our results support the hypothesis that GH can partially 
prevent the degradative and pro-inflammatory effects of IL-
1α in a dose-dependent manner, minimizing cartilage 
degradation by down-regulating aggrecanase activity and 
partially preventing inflammation by reducing the release of 
mediators of inflammation (PGE2, NO). 
The reduction of aggrecan degradation was associated 
with the higher concentration of GH (2 mg/mL) but not the 
lower (0.2 mg/mL), suggesting that the effect is dose 
dependent. No significant reduction of IL-1α-induced 
aggrecan loss was observed in explant cultures with CS and 
the addition of CS to GH did not further decrease the loss 
of aggrecan observed with GH. Our results are in agreement 
with other studies where IL-1 induced GAG release in 
culture media of porcine cartilage explants was decreased 
in the presence of 20 to 80 mM GH in a dose-dependent 
manner.35 Also, the release of aggrecanase products was 
reduced in the presence of 1.5 to 15 mM D-glucosamine in 
IL-1-induced rat chondrosarcoma cells and bovine cartilage 
explants.31 In the study of Dechant et al.,48 only the 
combination of glucosamine and CS at 250 µg/mL (1:1 
ratio) reduced IL-1-induced GAG release in equine 
cartilage explants, while the individual compounds did not 
have a significant effect. 
mRNA expression and activity of catabolic enzymes such 
as ADAMTS-4 and ADAMTS-5 are reported to be 
significantly increased in OA.48 The ability of 2 mg/mL GH 
(with or without 0.4 mg/mL CS) to inhibit cartilage 
degradation and prevent aggrecan release in the presence of IL-
1 may be partly attributed to the downregulation of the mRNA 
for these enzymes. In line with the previous results, 2 mg/mL 
GH (with or without 0.4 mg/mL CS) reduced the increase of 
ADAMTS-4 and ADAMTS-5 mRNA levels induced by IL-
1α. More specifically, although trends were similar for both 
enzyme genes, a significant (P = 0.014) decrease in IL-1 
induced mRNA expression was only obtained in the presence 
of GH for ADAMTS-5, suggesting that ADAMTS-5 may have 
a role in the degradation of aggrecan and that GH may prevent 
its activity through a reduction in production of the enzyme that 
is measurable by a reduction in mRNA. However, in the case 
of ADAMTS-4, we were able to demonstrate that the 
decreased IL-1-induced mRNA expression in the presence of 
GH correlated with a decrease in ADAMTS-4 activity, 
suggesting that ADAMTS-4 has a role in the degradation of 
aggrecan in this culture system. Surprisingly, mRNA 
expression for ADAMTS-4 and ADAMTS-5 was upregulated 
by 2 mg/mL GH alone. These results did not correlate with 
ADAMTS-4 activity or aggrecan degradation suggesting that 
there is another level of control downstream of mRNA 
expression. 
It has been previously shown that ADAMTS-5 is 
secreted as active enzyme through the removal of a 
prodomain by furin cleavage so undergoing 
posttranslational modification to become active.49 Indeed, a 
similar concentration of glucosamine as used in the present 
study impaired furin glycosylation compromising its 
conversion to active furin, which secondarily leads to failed 
activation of ADAMTS-5 zymogen.49 This supports our 
speculation that ADAMTS-5 activity is regulated 
posttranslationally and this process is downregulated by 
glucosamine. In our study, glucosamine was shown for the 
first time to decrease levels of ADAMTS-4 and ADAMTS-
5 aggrecan degradative products, together with its effects on 
mRNA expression and enzymatic activity of ADAMTS-4. 
The correlation between levels of degradative products with 
the enzymatic activity of ADAMTS-4 but not mRNA 
expression together with the findings of McCulloch et al.,49 
allow us to speculate that glucosamine affects mRNA 
expression of ADAMTS-4 but downregulates its activity at 
a posttranslation stage. In line with our results, 5 mM GH 
or glucosamine-3-sulfate significantly downregulated the 
mRNA expression of ADAMTS-4 and ADAMTS-5 in 
human osteoarthritic explants.50 Also consistent with our 
findings, in equine chondrocytes, 10 µg/mL glucosamine 
reduced IL-1-induced mRNA expression of ADAMTS-4 
and ADAMTS-5 while 5 to 50 µg/mL CS had no significant 
effect on the expression of these genes.34 In bovine cartilage 
explants, 5 µg/mL GH and 20 µg/mL CS individually or in 
combination suppressed IL-1-induced mRNA expression of 
ADAMTS-4 and ADAMTS-5.33,51,52 However, the effect of 
glucosamine alone on ADAMTS-5 mRNA expression and 
the increase in expression has only been previously shown 
by McCulloch et al.,49 making this a new finding and adding 
to the understanding of ADAMTS-4 and ADAMTS-5 
regulation in OA and by glucosamine. 
To complement our investigation, we tested the effects 
of GH and CS on inflammation by measuring levels of 
PGE2 and NO. PGE2 is one of the most characteristic 
prostaglandins found in joints with OA.53 Limiting its 
synthesis may possibly lessen inflammation and pain 
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involved in OA. NO synthesis is also associated with 
cartilage degradation and a reduction of proteoglycan 
synthesis. Therefore, limiting NO synthesis may be critical 
to delay the progression of OA and may also indicate a 
preventive effect of treatments. In our experiments, 2 
mg/mL GH alone and with 0.4 mg/mL CS reduced the 
increase of both PGE2 and NO synthesis caused by IL-1α. 
These results show that, in addition to preventing 
aggrecanase activity and cartilage degradation, GH could 
also prevent inflammation processes involved in OA. Our 
results are in agreement with studies where glucosamine or 
a combination with CS inhibited the release of PGE2 in 
cartilage explant induced by IL-1 or 
lipopolysaccharide.36,51,52 However, results of the 2 
compounds on NO release or of CS alone are mixed.51,52,54 
As IL-1α promotes the phosphorylation of signaling 
proteins leading to the activation of transcription factors 
such as nuclear factor-κB (NF-κB), and NF-κB stimulates 
the expression of iNOS and COX-2 involved in the 
synthesis of NO and PGE2 respectively, it is possible that in 
our study, the regulation of PGE2 and NO production 
stimulated by IL-1α and down-regulated by GH may have 
occurred via regulation of NF-κB. 
Although this study has found some positive effects of 
GH in an in vitro model of OA, the validation of the 
effectiveness of this neutraceutical would require 
confirmation using normal human cartilage. In addition, 
future studies would require different treatment periods 
with GH and CS as well as prolonged time points of 
evaluation for the metrics tested, that is, cartilage 
catabolism at the pathological IGD site and the release of 
inflammatory mediators. A significant drawback within the 
current type of in vitro studies is the assessment of 
bioavailabilty of either GH or CS after oral ingestion of the 
compounds either individually or combined. It is possible 
that CS may be broken down into smaller molecules, 
including GH, which from our results could be 
advantageous. Although, the absorption and bioavailability 
of such dietary supplements have not been fully clarified, 
ingested chondroitin and glucosamine are partially 
absorbed and it has been documented that some reach the 
synovial fluid and cartilage.38,55-57 
In conclusion, the results of this study, using an 
established model system, demonstrate that GH can 
partially prevent cartilage degradation generated by 
aggrecanases and reduce the release of inflammatory 
molecules. In contrast, and consistent with other studies, CS 
did not suppress the catabolism of aggrecan and the release 
of inflammatory factors following treatment with IL-1.34,54 
However, the beneficial effects of CS may be principally 
related to anabolic processes, such as its role in promoting 
collagen and proteoglycan synthesis,58 rather than the 
prevention of catabolic processes. 
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